TRANS-2-(3-(4-TERT-BUTYLPHENYL)-2-METHYLPROPYL)-6-HYDROXY-5,8A-DIMETHYLDECAHYDROISOQUINOLINIUM


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WGLCKRKVHNBWOJ-YOSHQONOSA-N
Smiles	CC(CN1CC[C@H]2[C@H](C)[C@@H](O)CC[C@]2(C)C1)Cc3ccc(cc3)C(C)(C)C
InChI	InChI=1S/C25H41NO/c1-18(15-20-7-9-21(10-8-20)24(3,4)5)16-26-14-12-22-19(2)23(27)11-13-25(22,6)17-26/h7-10,18-19,22-23,27H,11-17H2,1-6H3/t18?,19-,22-,23-,25+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H41NO
Molecular Weight	371.6
AlogP	5.79
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	23.47
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity
Ratio of compound I50 to delta8,14-cholestadien-3beta-ol Km for Zea mays (maize) delta 8,14-steroid 14-reductase	Zea mays	6.5e-05
Inhibition of Zea mays (maize) delta8,delta7-sterol isomerase	Zea mays	None
Inhibition of Zea mays (maize) cycloeucalenol-obtusifolial isomerase	Zea mays	100.0 nM
Inhibition of Zea mays (maize) microsomal delta 8,14-steroid 14-reductase using delta 8,14-cholestadienol as substrate after 90 min by GC analysis	Zea mays	70.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2253390
PubChem	76315516

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).